The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Challenges in translating molecular research into clinical practice for CLL treatment
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses key takeaways from this year’s ERIC meeting, highlighting the advances in detailed molecular workups for patients with chronic lymphocytic leukemia (CLL). Despite progress in research, there are challenges in translating these findings to clinical practice, particularly in using molecular markers and measurable residual disease (MRD) to guide treatment duration or reinitiation. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research grants and/or personal fees: Abbvie, Janssen, AZ, Genmab, Beigene, Galapagos, Takeda, CSL Behring, Lily, MSD, Octapharma.
